Iovance Biotherapeutics, Inc. (0JDK.L)
USD 7.6
(-2.69%)
USD 7.6
(-2.69%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -361.82 Million | -292.75 Million | -227.94 Million | -205.13 Million | -158.88 Million | -101.24 Million |
| Net Income | -444.03 Million | -395.89 Million | -342.25 Million | -259.58 Million | -197.55 Million | -123.58 Million |
| Depreciation & Amortization | 33.12 Million | 21.13 Million | 13.98 Million | 8.71 Million | 8.12 Million | 956 Thousand |
| Deferred income taxes | -3.47 Million | -120.4 Million | -90.74 Million | -61.27 Million | -27.81 Million | - |
| Stock-based compensation | 62.62 Million | 84.02 Million | 69.76 Million | 40.88 Million | 24.27 Million | 20.02 Million |
| Change in working capital | -11.34 Million | -2.89 Million | 24.55 Million | 2.98 Million | 10 Million | 2.67 Million |
| Other non-cash items | -2.18 Million | 121.28 Million | 96.76 Million | 63.14 Million | 24.07 Million | 19.1 Million |
| Investing Cash Flow | -155.24 Million | 256.45 Million | 132 Thousand | -317.85 Million | 90.02 Million | -386.27 Million |
| Investments in PPE | -22.29 Million | -20.42 Million | -37.57 Million | -46.79 Million | -6.91 Million | -1.19 Million |
| Acquisitions | -212.63 Million | -276.88 Million | -37.7 Million | 271.06 Million | -96.94 Million | - |
| Investment purchases | -205.9 Million | -245.81 Million | -725.2 Million | -947.66 Million | -417.65 Million | -426.08 Million |
| Sales/Maturities of investments | 285.58 Million | 522.69 Million | 762.91 Million | 676.6 Million | 514.6 Million | 41 Million |
| Other Investing Activities | 79.68 Million | 276.87 Million | 37.7 Million | -271.06 Million | 96.94 Million | -385.08 Million |
| Financing Cash Flow | 462.95 Million | 190.15 Million | 239.26 Million | 576.42 Million | 6.13 Million | 424.3 Million |
| Debt repayment | - | - | -1 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -2.79 Million | -2.64 Million | - | -284 Thousand | -312 Thousand | -223 Thousand |
| Common Stock Issuance | 465.75 Million | 192.79 Million | 238.26 Million | 576.42 Million | 6.13 Million | 424.3 Million |
| Other Financing Activities | 465.75 Million | -2.64 Million | 238.26 Million | 576.7 Million | 6.44 Million | 424.53 Million |
| Accounts receivables | -149 Thousand | - | - | - | - | - |
| Accounts payables | 4.82 Million | 5.88 Million | 6.97 Million | -2.96 Million | 12.7 Million | 1.5 Million |
| Inventory | -10.11 Million | - | - | - | - | - |
| Other working capital | -1.08 Million | -8.77 Million | 17.57 Million | 5.94 Million | -2.69 Million | 1.16 Million |
| Cash at beginning of period | 238.16 Million | 78.22 Million | 67.32 Million | 13.96 Million | 82.15 Million | 145.37 Million |
| Cash at end of period | 181.31 Million | 231.73 Million | 78.22 Million | 67.32 Million | 13.96 Million | 82.15 Million |
| Capital Expenditure | -22.29 Million | -20.42 Million | -37.57 Million | -46.79 Million | -6.91 Million | -1.19 Million |
| Effect of forex changes on cash | -2.74 Million | 1.00 | - | - | - | - |
| Net cash flow / Change in cash | -56.84 Million | 153.5 Million | 10.9 Million | 53.36 Million | -68.18 Million | -63.22 Million |
| Free Cash Flow | -384.11 Million | -313.18 Million | -265.51 Million | -251.92 Million | -165.8 Million | -102.44 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -97.1 Million | -112.97 Million | -444.03 Million | -116.37 Million | -113.76 Million | -106.52 Million |
| Depreciation & Amortization | 10.86 Million | 9.9 Million | 33.12 Million | 9.71 Million | 9.87 Million | 7.84 Million |
| Deferred income taxes | -1.45 Million | -1.4 Million | -3.47 Million | -1.75 Million | -1.24 Million | -477 Thousand |
| Stock-based compensation | 30.46 Million | 17.17 Million | 62.62 Million | 14.39 Million | 15.82 Million | 16.73 Million |
| Change in working capital | -28.32 Million | -32.54 Million | -6.52 Million | 11.88 Million | 5.89 Million | -11.47 Million |
| Other non-cash items | -14.33 Million | 47.19 Million | 130.78 Million | 21.49 Million | 44.31 Million | 32.21 Million |
| Investing Cash Flow | 40.21 Million | -111.5 Million | -155.24 Million | -72.84 Million | -79.01 Million | -156.77 Million |
| Investments in PPE | -442 Thousand | -4.17 Million | -22.29 Million | -3.52 Million | -3.57 Million | -9.52 Million |
| Acquisitions | - | -52.57 Million | -212.63 Million | 253 Thousand | -3.37 Million | -209.5 Million |
| Investment purchases | -74.33 Million | -141.76 Million | -205.9 Million | -107.56 Million | -93.01 Million | 147.25 Million |
| Sales/Maturities of investments | 115 Million | 87 Million | 285.58 Million | 38 Million | 20.95 Million | 62.25 Million |
| Other Investing Activities | 40.66 Million | -54.76 Million | 79.68 Million | -69.56 Million | -72.06 Million | 62.25 Million |
| Financing Cash Flow | 152.82 Million | 193.57 Million | 462.95 Million | 962 Thousand | 202.8 Million | 1.02 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1 Million | -4.7 Million | -2.79 Million | -186 Thousand | -379 Thousand | -301 Thousand |
| Common Stock Issuance | 153.82 Million | 198.27 Million | 465.75 Million | 1.14 Million | 203.17 Million | 1.32 Million |
| Other Financing Activities | 153.82 Million | -4.7 Million | -2.79 Million | -186 Thousand | -379 Thousand | -301 Thousand |
| Accounts receivables | -31.37 Million | -83 Thousand | -149 Thousand | -149 Thousand | 33 Thousand | -33 Thousand |
| Accounts payables | -10.39 Million | -5.81 Million | 4.82 Million | 11.42 Million | -9.76 Million | 146 Thousand |
| Inventory | -8.85 Million | -6.73 Million | -10.11 Million | -923 Thousand | 354 Thousand | -9.54 Million |
| Other working capital | 11.9 Million | -19.91 Million | -1.08 Million | 1.53 Million | 15.26 Million | -2.03 Million |
| Cash at beginning of period | 140.61 Million | 114.88 Million | 231.73 Million | 267.72 Million | 230.01 Million | 543.48 Million |
| Cash at end of period | 235.1 Million | 134.18 Million | 114.88 Million | 114.88 Million | 267.72 Million | 230.01 Million |
| Capital Expenditure | -442 Thousand | -4.17 Million | -22.29 Million | -3.52 Million | -3.57 Million | -9.52 Million |
| Effect of forex changes on cash | -125 Thousand | -491 Thousand | -2.74 Million | 3.02 Million | -1.99 Million | -3.76 Million |
| Net cash flow / Change in cash | 94.49 Million | 19.29 Million | -116.84 Million | -152.83 Million | 37.71 Million | -313.47 Million |
| Free Cash Flow | -98.87 Million | -126.45 Million | -384.11 Million | -87.49 Million | -87.66 Million | -103.47 Million |
002737
300376
SRI
PODC
4263
8300